News | October 30, 2025
Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The antibody was designed and developed at Abzena’s Cambridge, UK,
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
